Home » Topics » Disease categories and therapies » Musculoskeletal

Musculoskeletal
RSS

New approval for Bristol-Myers Squibb's Orencia in Europe

Sep. 7, 2016

Reata Pharmaceuticals presents nitric oxide production inhibitors

Sep. 7, 2016

FDA awards Santhera USD 246,000 for the development of omigapil

Sep. 1, 2016

MK-8449: a second generation SYK/ZAP70 inhibitor from Merck

Sep. 1, 2016

Facio establishes tool to aid in FSHD drug discovery

Sep. 1, 2016

FDA approves biosimilar etanercept Erelzi

Aug. 31, 2016

Eli Lilly begins phase II trial of LY-3337641 in patients with rheumatoid arthritis

Aug. 30, 2016

Bristol-Myers Squibb initiates phase I trial of BMS-986195

Aug. 29, 2016

Ferring signs licensing agreement with Seikagaku for condoliase

Aug. 29, 2016

Researchers from Genentech identify novel potent and selective NIK inhibitors

Aug. 26, 2016

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 28, 2026.
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
News in brief
BioWorld Asia
BioWorld Asia briefs for April 28, 2026
Sichuan Kelun Pharmaceutical Research Institute discovers GPR6 inverse agonists
BioWorld Science
Sichuan Kelun Pharmaceutical Research Institute Co. Ltd. has identified G protein-coupled receptor 6 (GPR6) inverse agonists reported to be useful for the...
Grace Therapeutics hits CRL setback with GTx-104 despite positive trial
BioWorld
Grace Therapeutics Inc.’s hopes of becoming the first company in decades to update the standard of care in aneurysmal subarachnoid hemorrhage were delayed after...